Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with one of the following cancer types, confirmed by laboratory tissue testing: pancreatic cancer, certain virus-linked cancers (such as cervical, head and neck, nasal, or nasopharyngeal cancers), Kaposi's sarcoma, non-small cell lung cancer, soft-tissue sarcoma, bladder cancer, or triple negative breast cancer (confirm specific cancer type and any additional confirmation requirements with trial site)
• People whose cancer has spread to other parts of the body (metastatic disease)
• People aged 18 years or older
• People who are well enough to carry out daily activities with little or no limitation, as measured by a standard medical performance scale (ECOG score of 0 or 1)
• People who have at least two areas of cancer in the body: one that can be treated with radiotherapy (no larger than 3 cm and not previously irradiated), and one separate measurable area of at least 10 mm that will not be treated with radiotherapy
• People with a life expectancy of more than 6 months
• People who have at least one tumour area that is safe to biopsy (take a small tissue sample from) for research purposes
• People for whom stored tumour tissue from a previous biopsy or surgery is available for research
• People whose cancer has progressed and for whom no other approved treatment is considered likely to provide meaningful benefit, based on the treating doctor's judgement
• People who have previously received a specific type of immunotherapy (anti-PD-1/L1) must meet additional conditions — including having responded to or stabilised on that treatment before progressing, having received at least two doses, and having shown disease progression within 18 weeks of the last dose (this applies to specific patient groups only; confirm with trial site)
• People with adequate blood, kidney, liver, and metabolic function as assessed by standard tests
• People who have not had another active cancer requiring treatment
• People who have waited at least three weeks since their last chemotherapy, immunotherapy, or radiation treatment
• People who have recovered from most side effects of previous treatments (minor hair loss and mild nerve-related symptoms may be acceptable)
• Women who could become pregnant must have a negative blood pregnancy test within 7 days before joining the trial
• Both women and men must agree to use effective contraception throughout treatment and for five months after treatment ends
• People who have read, understood, and voluntarily signed a consent form before any study procedures begin
• People covered by the French social security system, as required under French law

Who may not be able to join:

• People who have previously been treated with a type of drug called a TLR agonist
• People who have cancer that has spread to the brain or spinal fluid and is either growing or causing symptoms
• People who are pregnant or currently breastfeeding
• People who have taken part in another medical or treatment study within the last 30 days
• People with a known allergy to CHO cell products or to any of the study drugs or their ingredients
• People with a history of severe allergic (anaphylactic) reactions to certain types of laboratory-made antibodies or proteins used in medicines
• People who have taken immunosuppressive medications (medicines that reduce immune system activity, such as cyclophosphamide, methotrexate, or anti-TNF drugs) within the 2 weeks before joining
• People who have had major surgery, an open biopsy, or a serious injury within 28 days before joining
• People with significant heart conditions, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the last 6 months, uncontrolled irregular heartbeat, known low heart pumping function, or a history of inflammation around the heart
• People who are legally detained or under court-appointed guardianship
• People who have previously had an organ transplant or a stem cell transplant from a donor
• People with known significant liver disease, including active hepatitis, cirrhosis, or inherited liver conditions
• People with a history of serious abdominal inflammation in the last 12 months, such as diverticulitis, peptic ulcers, or colitis
• People with a history of certain autoimmune diseases (conditions where the immune system attacks the body), such as lupus, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease, among others
• People with a history of certain lung scarring or inflammation conditions, or who show signs of active lung inflammation on a scan at screening
• People with poorly controlled type 2 diabetes, defined as a fasting blood sugar level of 160 mg/dL (8.8 mmol/L) or higher at screening
• People who have had a severe infection within 2 weeks before joining, including COVID-19 requiring hospitalisation, a bloodstream infection, or severe pneumonia
• People who have taken antibiotic tablets or infusions as treatment within the 2 weeks before joining
• People with spinal cord compression that has not been fully treated, or whose previously treated spinal cord compression has not been confirmed as stable for at least 14 days before joining
• People who have received a live vaccine within 4 weeks before starting the study medication
• People with known active hepatitis B or C, HIV, or a known history of tuberculosis
• People with a current eye (retinal) disorder confirmed by eye examination
• People who wear contact lenses and are unable to switch to wearing glasses

Important: Always verify eligibility with the trial site directly before applying.